EcoDrugPlus

C-Type Lectin Domain Family 4, Member A3

Ensembl ID : ENSMSIG00000028862
Gene Symbol: CLEC4A3
1 Cross references
723 Possible Orthologues:

C-Type Lectin Domain Family 4, Member B1

Ensembl ID : ENSMSIG00000028845
Gene Symbol: CLEC4B1
1 Cross references
715 Possible Orthologues:

C-Type Lectin Domain Family 4, Member B2

Ensembl ID : ENSMSIG00000016040
Gene Symbol: CLEC4B2
1 Cross references
722 Possible Orthologues:

Dna Methyltransferase (Cytosine-5) 1

Ensembl ID : ENSMSIG00000017200
Gene Symbol: DNMT1
1 Cross references
221 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSMSIG00000014018
Gene Symbol: EPHA2
1 Cross references
139 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMSIG00000021215
Gene Symbol: EPHA3
1 Cross references
230 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSMSIG00000009713
Gene Symbol: EPHB4
1 Cross references
181 Possible Orthologues:

Fms-Like Tyrosine Kinase 1

Ensembl ID : ENSMSIG00000023642
Gene Symbol: FLT1
1 Cross references
213 Possible Orthologues:

Fms-Like Tyrosine Kinase 3

Ensembl ID : ENSMSIG00000023851
Gene Symbol: FLT3
1 Cross references
148 Possible Orthologues:

Fms-Like Tyrosine Kinase 4

Ensembl ID : ENSMSIG00000014828
Gene Symbol: FLT4
1 Cross references
210 Possible Orthologues:

Finkel-Biskis-Reilly Murine Sarcoma Virus (Fbr-Musv) Ubiquitously Expressed (Fox Derived)

Ensembl ID : ENSMSIG00000030270
Gene Symbol: FAU
1 Cross references
275 Possible Orthologues:

Fyn Proto-Oncogene

Ensembl ID : ENSMSIG00000001064
Gene Symbol: FYN
1 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).